XML 15 R5.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
Total
Preferred stock
Common stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income (loss)
Non- controlling interest
Beginning balance (shares) at Dec. 31, 2017   23 90,357,644        
Beginning balance at Dec. 31, 2017 $ 142,488,809 $ 0 $ 90,358 $ 665,775,504 $ (523,356,317) $ (117,005) $ 96,269
Exercise of stock options for cash and vesting of RSUs, net of tax payments (shares)     347,287        
Exercise of stock options for cash and vesting of RSUs, net of tax payments (506,403)   $ 347 (506,750)      
Stock-based compensation 3,575,750     3,575,750      
Net loss attributable to common stockholders (32,350,828)       (32,350,828)    
Unrealized gain (loss) on short-term investments, net of tax (112,765)         (112,765)  
Ending balance (shares) at Mar. 31, 2018   23 90,704,931        
Ending balance at Mar. 31, 2018 113,094,563 $ 0 $ 90,705 668,844,504 (555,475,779) (461,136) 96,269
Beginning balance (shares) at Dec. 31, 2017   23 90,357,644        
Beginning balance at Dec. 31, 2017 142,488,809 $ 0 $ 90,358 665,775,504 (523,356,317) (117,005) 96,269
Net loss attributable to common stockholders (38,989,953)            
Unrealized gain (loss) on short-term investments, net of tax (250,015)            
Ending balance (shares) at Jun. 30, 2018   23 91,474,395        
Ending balance at Jun. 30, 2018 111,491,820 $ 0 $ 91,474 674,017,367 (562,114,904) (598,386) 96,269
Beginning balance (shares) at Mar. 31, 2018   23 90,704,931        
Beginning balance at Mar. 31, 2018 113,094,563 $ 0 $ 90,705 668,844,504 (555,475,779) (461,136) 96,269
Issuance of common stock for cash (shares)     407,429        
Issuance of common stock for cash 1,973,401   $ 407 1,972,994      
Exercise of stock options for cash and vesting of RSUs, net of tax payments (shares)     362,035        
Exercise of stock options for cash and vesting of RSUs, net of tax payments 611,061   $ 362 610,699      
Stock-based compensation 2,589,170     2,589,170      
Net loss attributable to common stockholders (6,639,125)       (6,639,125)    
Unrealized gain (loss) on short-term investments, net of tax (137,250)         (137,250)  
Ending balance (shares) at Jun. 30, 2018   23 91,474,395        
Ending balance at Jun. 30, 2018 111,491,820 $ 0 $ 91,474 674,017,367 (562,114,904) (598,386) 96,269
Beginning balance (shares) at Dec. 31, 2018   23 97,225,810        
Beginning balance at Dec. 31, 2018 87,032,407 $ 0 $ 97,226 707,794,215 (620,426,436) (528,867) 96,269
Issuance of common stock for cash (shares)     183,200        
Issuance of common stock for cash 907,330   $ 183 907,147      
Exercise of stock options for cash and vesting of RSUs, net of tax payments (shares)     525,000        
Exercise of stock options for cash and vesting of RSUs, net of tax payments (719,397)   $ 525 (719,922)      
Equity component of issuance of convertible notes 15,752,698     15,752,698      
Stock-based compensation 3,432,796     3,432,796      
Acquisition of non-controlling interest in Geneos 3,030,107           3,030,107
Net loss attributable to common stockholders (29,288,867)       (29,219,262)   (69,605)
Unrealized gain (loss) on short-term investments, net of tax 819,177         819,177  
Ending balance (shares) at Mar. 31, 2019   23 97,934,010        
Ending balance at Mar. 31, 2019 80,966,251 $ 0 $ 97,934 727,166,934 (649,645,698) 290,310 3,056,771
Beginning balance (shares) at Dec. 31, 2018   23 97,225,810        
Beginning balance at Dec. 31, 2018 87,032,407 $ 0 $ 97,226 707,794,215 (620,426,436) (528,867) 96,269
Net loss attributable to common stockholders (58,867,943)            
Unrealized gain (loss) on short-term investments, net of tax 1,260,722            
Ending balance (shares) at Jun. 30, 2019   23 98,584,371        
Ending balance at Jun. 30, 2019 56,478,073 $ 0 $ 98,584 731,819,389 (679,032,924) 731,855 2,861,169
Beginning balance (shares) at Mar. 31, 2019   23 97,934,010        
Beginning balance at Mar. 31, 2019 80,966,251 $ 0 $ 97,934 727,166,934 (649,645,698) 290,310 3,056,771
Issuance of common stock for cash (shares)     476,600        
Issuance of common stock for cash 1,388,986   $ 476 1,388,510      
Exercise of stock options for cash and vesting of RSUs, net of tax payments (shares)     173,761        
Exercise of stock options for cash and vesting of RSUs, net of tax payments (81,259)   $ 174 (81,433)      
Stock-based compensation 3,355,195     3,345,378     9,817
Cost of acquisition of non-controlling interest in Geneos (13,569)           (13,569)
Net loss attributable to common stockholders (29,579,076)       (29,387,226)   (191,850)
Unrealized gain (loss) on short-term investments, net of tax 441,545         441,545  
Ending balance (shares) at Jun. 30, 2019   23 98,584,371        
Ending balance at Jun. 30, 2019 $ 56,478,073 $ 0 $ 98,584 $ 731,819,389 $ (679,032,924) $ 731,855 $ 2,861,169